The prognostic impact of abnormally expressed, long noncoding RNAs in acute myeloid leukemia: a meta-analysis

Objectives:A growing number of studies demonstrate that long noncoding RNAs (lncRNAs) could act as biomarkers to determine the prognosis of acute myeloid leukemia (AML) patients. Nonetheless, the significance of lncRNAs in AML prognosis remains unclear. We conducted a meta-analysis to assess the prognostic indicators of abnormally expressed lncRNAs in AML. Methods:Literature was searched using PubMed, EMBASE, and Web of Science databases up to November 10, 2018. Results:Thirteen studies with 2755 individuals were included. The abnormal expression of lncRNAs was associated with worse overall survival (OS) in AML patients, especially in cytogenetically normal AML (CN-AML), and was associated with shorter disease-free survival and event-free survival. Subgroup analysis showed that high levels ofHOTAIRandTUG1were associated with poor OS. Discussion:Overexpression of lncRNAHOTAIRandTUG1were reported in two separate studies, and correlated with worse AML prognoses. Conclusion:Abnormally expressed lncRNAs are significantly related to worse prognoses of AML patients and might serve as potential prognostic markers to predict the prognosis of AML patients.